A total of 489 kidney disease progression outcomes accrued in those with an eGFR less than 30 mL/min per 1·73 m2 in those two trials.7, 8, 52 Although some clinical practice guidelines have started recommending use of SGLT2 inhibitors in type 2 diabetes at eGFRs down to 20 mL/min per 1·73 m2 (based on grade B levels of evidence),53, 54 many other recommendations limit initiation to those with eGFR greater than 25 mL/min per 1·73 m2 or 30 mL/min per 1·73 m2. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.